What question did this study set out to answer?

February 2, 2026Open Access

Safety of a Tailored Gadolinium-Based Contrast Agent Protocol Considering Excretion Pathways in Patients with Renal Impairment

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study evaluates outcomes of a tailored gadolinium protocol in patients with kidney issues, suggesting safety for clinical practice.

Evaluate the safety and clinical outcomes of a tailored gadolinium-based contrast agent protocol for patients with renal impairment.
Conducted a single-center retrospective study.
Included patients with renal impairment who underwent GBCA-enhanced MRI from 2015 to 2022.
Recommended specific GBCAs based on chronic kidney disease (CKD) stage and serum bilirubin levels.
Evaluated occurrences of nephrogenic systemic fibrosis (NSF) and gadolinium deposition in brain tissues.
288 patients underwent 716 GBCA-enhanced MRI examinations.
No cases of NSF or gadolinium deposition in brain tissues were identified.
Gadoxetate disodium was used in 597 examinations for CKD stage 4 and 5 patients.

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective study evaluates outcomes of a tailored gadolinium protocol in patients with kidney issues, suggesting safety for clinical practice.